The U.S. Food and Drug Administration (FDA) has approved significant safety updates for Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for Duchenne muscular dystrophy (DMD). The updated labeling now carries a Boxed Warning, highlighting risks of severe liver injury, including fatal acute liver failure. The therapy's indication is now restricted to ambulatory patients aged four and above with a confirmed DMD gene mutation, removing prior approval for non-ambulatory patients due to safety concerns.
These regulatory changes arise after reports of fatal acute liver failure in non-ambulatory pediatric DMD patients and one serious but non-fatal case involving severe liver complications. Both fatalities involved rapid onset of heightened liver enzymes requiring hospitalization within two months post-infusion. In response, the manufacturer voluntarily paused Elevidys use in non-ambulatory patients pending safety review.
In addition to the Boxed Warning and revised indication, the new label includes a Limitations of Use section to guide clinical decisions, expanded warnings, dosage modifications, updates on adverse reactions, and detailed information for patient counseling. A Medication Guide has also been introduced to inform patients and caregivers about risks and necessary monitoring.
Patient safety monitoring is emphasized with recommendations for weekly liver function testing for at least three months after treatment and cardiac troponin-I testing for one month. Patients are advised to remain close to medical facilities for at least two months post-infusion. Immediate medical evaluation is essential if symptoms like yellowing of the skin or eyes, mental status changes, or missed corticosteroid doses occur. The immunosuppressive effects of corticosteroids heighten infection risks, warranting close attention.
Contraindications include patients with deletions involving DMD exons 8 and/or 9. Limitations of Use include preexisting liver impairment, recent vaccinations, or active infections. To further evaluate safety, the FDA requires a postmarketing observational study enrolling roughly 200 patients with Duchenne, following liver function over at least a year.
Healthcare providers and patients are urged to report adverse events, particularly liver-related issues, via FDA MedWatch and Sarepta Therapeutics. The FDA remains committed to ongoing monitoring to safeguard patients while allowing access to this innovative gene therapy.
